NCT00869908 - Observational Study on the Effect of NovoMix® 30, Levemir® or NovoRapid® (Alone or Combined) in Type 2 Diabetics Previously Treated With Anti-diabetic Medication | Biotech Hunter

Enrollment

66,726

Participants

Timeline

Start Date

November 30, 2008

Primary Completion Date

March 31, 2011

Study Completion Date

March 31, 2011

Conditions

DiabetesDiabetes Mellitus, Type 2

Interventions

DRUG

insulin aspart

Start dose and frequency to be prescribed by the physician as a result of the normal clinical evaluation

DRUG

insulin detemir

Start dose and frequency to be prescribed by the physician as a result of the normal clinical evaluation

DRUG

biphasic insulin aspart

Start dose and frequency to be prescribed by the physician as a result of the normal clinical evaluation

Trial Locations (22)

1053

Novo Nordisk Investigational Site, Tunisia

1206

Novo Nordisk Investigational Site, Dhaka

1605

Novo Nordisk Investigational Site, Manila

3542

Novo Nordisk Investigational Site, Riyadh

11844

Novo Nordisk Investigational Site, Amman

12520

Novo Nordisk Investigational Site, Jakarta

16035

Novo Nordisk Investigational Site, Algiers

20000

Novo Nordisk Investigational Site, Casablanca

34335

Novo Nordisk Investigational Site, Istanbul

100004

Novo Nordisk Investigational Site, Beijing

119330

Novo Nordisk Investigational Site, Moscow

307684

Novo Nordisk Investigational Site, Singapore

560001

Novo Nordisk Investigational Site, Bangalore

B1636DSU

Novo Nordisk Investigational Site, Prov. de Buenos Aires

Unknown

Novo Nordisk Investigational Site, Cairo

Novo Nordisk Investigational Site, Tehran

Novo Nordisk Investigational Site, Tripoli

Novo Nordisk Investigational Site, Selangor Darul Ehsan

Novo Nordisk Investigational Site, Mexico City

Novo Nordisk Investigational Site, Karachi

Novo Nordisk Investigational Site, Taipei

137-920

Novo Nordisk Investigational Site, Seoul